September 29, 2022

tvadvideos

Consummate Business Technicians

Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer’s Disease

Acumen Pharmaceuticals, Inc.

Acumen Prescription drugs, Inc.

Acumen targeted on building investigational monoclonal antibody concentrating on amyloid beta oligomers

CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (World NEWSWIRE) — Acumen Prescribed drugs, Inc. (NASDAQ: ABOS), a medical phase biopharmaceutical organization centered on the development of novel specific therapeutics for Alzheimer’s illness (Ad), right now announced that Frontiers in Neuroscience printed a summary of preclinical evidence supporting ACU193, a monoclonal antibody that selectively targets harmful soluble Aβ oligomers (AβOs) for the prospective treatment of early Alzheimer’s disease. The short article is titled “ACU193: An immunotherapeutic poised to take a look at the amyloid β oligomer speculation of Alzheimer’s disease” and can be accessed here.

Studies recommend that AβO-mediated neuronal toxicity is immediately liable for Alzheimer’s-connected memory and cognitive issues. AβOs have been uncovered to interact inside synapses of mind cells referred to as neurons, which sales opportunities to altered neuronal functionality, and might initiate and perpetuate the process of neurodegeneration, eventually top to cell death.

“We are ever more mastering extra about the unique roles particular entities in the amyloid cascade, like AβOs, perform in Alzheimer’s condition pathology,” claimed Eric Siemers, M.D., Main Medical Officer at Acumen Prescription drugs and co-creator of the publication. “We think concentrating on AβOs stays a promising solution due to the fact proof implies they are the most poisonous kind of Aβ and may be liable for the memory impairment and cognitive drop in Alzheimer’s patients. We count on our ongoing Section I scientific trial of ACU193 to present even more explanatory facts and evidence of mechanism facts that will probably pave the way in direction of screening of this hypothesis in much larger scientific studies. We seem forward to sharing the success from our Stage I medical demo when accessible.”

Acumen thinks ACU193 has lots of vital homes required for a profitable therapeutic and selectively binds to AβOs. Preclinical facts highlights in the publication on ACU193 consist of:

  • ACU193 selectively binds AβOs with 650-fold selectivity when compared to Aβ monomers with minimal to no binding to fibrillar Aβ in vitro

  • ACU193 prevents AβO-induced disruption of lengthy-term potentiation (LTP), a procedure of strengthening synapses that is vital for studying and memory

  • ACU193 can bind to a wide vary of AβOs with varying molecular weights

  • The parent of ACU193, termed ACU3B3, helps prevent AβO-induced disruption of calcium homeostasis, an early indicator of mobile dysfunction

  • ACU3B3 drastically enhanced behavioral deficits across different assessments when administered to animal types at an age when AβO levels were measurable but prior to plaque deposition

Present therapeutics targeting amyloid plaque result in amyloid associated imaging abnormalities (ARIA), together with cerebral edema (ARIA-E) or microhemorrhage (ARIA-H), which might complicate the utility of these medicines. Existing preclinical information counsel that ACU193 is not envisioned to elicit ARIA aspect results owing to its high selectivity for AβOs and limited binding to plaque.

About Acumen Prescribed drugs, Inc.
Acumen, headquartered in Charlottesville, VA, with medical functions dependent in Carmel, IN, is a clinical stage biopharmaceutical corporation establishing a novel ailment-modifying approach to address Alzheimer’s disease. Acumen’s scientific founders pioneered exploration on AβOs, which a expanding human body of proof implies are key triggers of Alzheimer’s condition pathology. Acumen is now centered on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets harmful AβOs in INTERCEPT-Advert, a Phase I medical demo involving early Alzheimer’s disorder clients. For extra data, stop by www.acumenpharm.com.

Forward-Looking Statements
This press launch includes forward‐looking statements within just the which means of The Private Securities Litigation Reform Act of 1995. Any assertion describing Acumen’s ambitions, anticipations, economical or other projections, intentions or beliefs is a forward‐looking statement and need to be deemed an at‐risk assertion. Words and phrases this sort of as “believes,” “expects,” “anticipates,” “could,” “would,” “seeks,” “aims,” “plans,” “potential,” “will” and comparable expressions are supposed to establish forward‐looking statements, although not all forward‐looking statements include these identifying phrases. Forward‐looking statements contain statements about Acumen’s business and the therapeutic potential of Acumen’s solution prospect, ACU193, which includes its potential for improved basic safety and efficacy as in contrast to other monoclonal antibodies in advancement, as well as the anticipations about the INTERCEPT‐AD trial and expectations with regard to the job of AβOs in the possible cure of Alzheimer’s ailment. These statements are primarily based upon the existing beliefs and expectations of Acumen management, and are issue to particular elements, challenges and uncertainties, specially all those inherent in the process of identifying, creating and commercializing harmless and productive human therapeutics. These kinds of dangers may perhaps be amplified by the impacts of the COVID‐19 pandemic. These and other hazards concerning Acumen’s systems are described in extra element in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s Annual Report on Kind 10‐K for the year ended December 31, 2021, filed with the SEC on March 28, 2021, which is out there on the SEC’s internet site at www.sec.gov. Copies of these and other files are accessible from Acumen. Further info will be designed obtainable in other filings that Acumen can make from time to time with the SEC. These forward‐looking statements discuss only as of the day hereof, and Acumen expressly disclaims any obligation to update or revise any forward‐looking statement, other than as normally expected by law, regardless of whether, as a final result of new information and facts, long term gatherings or usually.

Contacts:

Media:
[email protected]

Investors:
[email protected]